Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma

Luigi Corti, Lamberto Toniolo, Caterina Boso, Flavio Colaut, Davide Fiore, Pier Carlo Muzzio, Michael I. Koukourakis, Renzo Mazzarotto, Michele Pignataro, Lucio Loreggian, Guido Sotti

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent non-small-cell lung cancer (NSCLC). Methods and Materials: From June 1989 to November 2004, 40 patients with 50 NSCLC were treated with PDT. Twelve cases were inoperable for medical reasons and were staged as T1N0M0, and 28 had recurrent in situ carcinoma. Patients with residual disease after PDT received definitive radiotherapy and/or brachytherapy. Follow-up ranged from 6 to 167 months (median 43.59). Twenty of the 40 patients received i.v. injections of hematoporphyrin derivative (5 mg/kg), the other 20 had injections of porfimer sodium (Photofrin, 2 mg/kg). An argon dye laser (630 nm wavelength, 200-300 J/cm2) was used for light irradiation in 24 of the 40 patients, a diode laser (Diomed, 630 nm wavelength, 100-200 J/cm2) in the other 16. Results: PDT obtained a 72% complete response (CR) rate (36/50 treated lesions), that is 27 CR among the 37 Tis carcinomas and 9 among the 13 T1 cases. Kaplan-Meier curves showed a mean overall survival (OS) of 75.59 months (median 91.4 months). Two- and 5-year OS rates were 72.78% and 59.55%. The mean and median survival rates for patients with Tis stage were 86.5 and 120.4 months, respectively (standard error 9.50) and for patients with T1 disease they were 45.78 and 35.71 months, respectively; the difference was statistically significant (P = 0.03). No severe early or late PDT-related adverse events were recorded. Conclusions: PDT is effective in early primary or recurrent NSCLC, resulting in a CR rate of 72%. The incorporation of PDT in standard clinical practice, in combination with radiotherapy, warrants further investigation.

Original languageEnglish
Pages (from-to)394-402
Number of pages9
JournalLasers in Surgery and Medicine
Volume39
Issue number5
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Carcinoma in Situ
Photochemotherapy
Non-Small Cell Lung Carcinoma
Survival
Dihematoporphyrin Ether
Radiotherapy
Survival Rate
Hematoporphyrin Derivative
Dye Lasers
Semiconductor Lasers
Injections
Argon
Brachytherapy
Carcinoma
Light

Keywords

  • Hematoporphyrin derivative
  • Non-small-cell lung cancer
  • Photodynamic therapy
  • Photofrin

ASJC Scopus subject areas

  • Surgery

Cite this

Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. / Corti, Luigi; Toniolo, Lamberto; Boso, Caterina; Colaut, Flavio; Fiore, Davide; Muzzio, Pier Carlo; Koukourakis, Michael I.; Mazzarotto, Renzo; Pignataro, Michele; Loreggian, Lucio; Sotti, Guido.

In: Lasers in Surgery and Medicine, Vol. 39, No. 5, 06.2007, p. 394-402.

Research output: Contribution to journalArticle

Corti, L, Toniolo, L, Boso, C, Colaut, F, Fiore, D, Muzzio, PC, Koukourakis, MI, Mazzarotto, R, Pignataro, M, Loreggian, L & Sotti, G 2007, 'Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma', Lasers in Surgery and Medicine, vol. 39, no. 5, pp. 394-402. https://doi.org/10.1002/lsm.20513
Corti, Luigi ; Toniolo, Lamberto ; Boso, Caterina ; Colaut, Flavio ; Fiore, Davide ; Muzzio, Pier Carlo ; Koukourakis, Michael I. ; Mazzarotto, Renzo ; Pignataro, Michele ; Loreggian, Lucio ; Sotti, Guido. / Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. In: Lasers in Surgery and Medicine. 2007 ; Vol. 39, No. 5. pp. 394-402.
@article{d65393f74b434e4a8574dac5d9ebc22b,
title = "Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma",
abstract = "Purpose: The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent non-small-cell lung cancer (NSCLC). Methods and Materials: From June 1989 to November 2004, 40 patients with 50 NSCLC were treated with PDT. Twelve cases were inoperable for medical reasons and were staged as T1N0M0, and 28 had recurrent in situ carcinoma. Patients with residual disease after PDT received definitive radiotherapy and/or brachytherapy. Follow-up ranged from 6 to 167 months (median 43.59). Twenty of the 40 patients received i.v. injections of hematoporphyrin derivative (5 mg/kg), the other 20 had injections of porfimer sodium (Photofrin, 2 mg/kg). An argon dye laser (630 nm wavelength, 200-300 J/cm2) was used for light irradiation in 24 of the 40 patients, a diode laser (Diomed, 630 nm wavelength, 100-200 J/cm2) in the other 16. Results: PDT obtained a 72{\%} complete response (CR) rate (36/50 treated lesions), that is 27 CR among the 37 Tis carcinomas and 9 among the 13 T1 cases. Kaplan-Meier curves showed a mean overall survival (OS) of 75.59 months (median 91.4 months). Two- and 5-year OS rates were 72.78{\%} and 59.55{\%}. The mean and median survival rates for patients with Tis stage were 86.5 and 120.4 months, respectively (standard error 9.50) and for patients with T1 disease they were 45.78 and 35.71 months, respectively; the difference was statistically significant (P = 0.03). No severe early or late PDT-related adverse events were recorded. Conclusions: PDT is effective in early primary or recurrent NSCLC, resulting in a CR rate of 72{\%}. The incorporation of PDT in standard clinical practice, in combination with radiotherapy, warrants further investigation.",
keywords = "Hematoporphyrin derivative, Non-small-cell lung cancer, Photodynamic therapy, Photofrin",
author = "Luigi Corti and Lamberto Toniolo and Caterina Boso and Flavio Colaut and Davide Fiore and Muzzio, {Pier Carlo} and Koukourakis, {Michael I.} and Renzo Mazzarotto and Michele Pignataro and Lucio Loreggian and Guido Sotti",
year = "2007",
month = "6",
doi = "10.1002/lsm.20513",
language = "English",
volume = "39",
pages = "394--402",
journal = "Lasers in Surgery and Medicine",
issn = "0196-8092",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma

AU - Corti, Luigi

AU - Toniolo, Lamberto

AU - Boso, Caterina

AU - Colaut, Flavio

AU - Fiore, Davide

AU - Muzzio, Pier Carlo

AU - Koukourakis, Michael I.

AU - Mazzarotto, Renzo

AU - Pignataro, Michele

AU - Loreggian, Lucio

AU - Sotti, Guido

PY - 2007/6

Y1 - 2007/6

N2 - Purpose: The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent non-small-cell lung cancer (NSCLC). Methods and Materials: From June 1989 to November 2004, 40 patients with 50 NSCLC were treated with PDT. Twelve cases were inoperable for medical reasons and were staged as T1N0M0, and 28 had recurrent in situ carcinoma. Patients with residual disease after PDT received definitive radiotherapy and/or brachytherapy. Follow-up ranged from 6 to 167 months (median 43.59). Twenty of the 40 patients received i.v. injections of hematoporphyrin derivative (5 mg/kg), the other 20 had injections of porfimer sodium (Photofrin, 2 mg/kg). An argon dye laser (630 nm wavelength, 200-300 J/cm2) was used for light irradiation in 24 of the 40 patients, a diode laser (Diomed, 630 nm wavelength, 100-200 J/cm2) in the other 16. Results: PDT obtained a 72% complete response (CR) rate (36/50 treated lesions), that is 27 CR among the 37 Tis carcinomas and 9 among the 13 T1 cases. Kaplan-Meier curves showed a mean overall survival (OS) of 75.59 months (median 91.4 months). Two- and 5-year OS rates were 72.78% and 59.55%. The mean and median survival rates for patients with Tis stage were 86.5 and 120.4 months, respectively (standard error 9.50) and for patients with T1 disease they were 45.78 and 35.71 months, respectively; the difference was statistically significant (P = 0.03). No severe early or late PDT-related adverse events were recorded. Conclusions: PDT is effective in early primary or recurrent NSCLC, resulting in a CR rate of 72%. The incorporation of PDT in standard clinical practice, in combination with radiotherapy, warrants further investigation.

AB - Purpose: The role of photodynamic therapy (PDT) in the treatment of small cancers has been established in several clinical studies. Here, we report on the efficacy of PDT for early inoperable or recurrent non-small-cell lung cancer (NSCLC). Methods and Materials: From June 1989 to November 2004, 40 patients with 50 NSCLC were treated with PDT. Twelve cases were inoperable for medical reasons and were staged as T1N0M0, and 28 had recurrent in situ carcinoma. Patients with residual disease after PDT received definitive radiotherapy and/or brachytherapy. Follow-up ranged from 6 to 167 months (median 43.59). Twenty of the 40 patients received i.v. injections of hematoporphyrin derivative (5 mg/kg), the other 20 had injections of porfimer sodium (Photofrin, 2 mg/kg). An argon dye laser (630 nm wavelength, 200-300 J/cm2) was used for light irradiation in 24 of the 40 patients, a diode laser (Diomed, 630 nm wavelength, 100-200 J/cm2) in the other 16. Results: PDT obtained a 72% complete response (CR) rate (36/50 treated lesions), that is 27 CR among the 37 Tis carcinomas and 9 among the 13 T1 cases. Kaplan-Meier curves showed a mean overall survival (OS) of 75.59 months (median 91.4 months). Two- and 5-year OS rates were 72.78% and 59.55%. The mean and median survival rates for patients with Tis stage were 86.5 and 120.4 months, respectively (standard error 9.50) and for patients with T1 disease they were 45.78 and 35.71 months, respectively; the difference was statistically significant (P = 0.03). No severe early or late PDT-related adverse events were recorded. Conclusions: PDT is effective in early primary or recurrent NSCLC, resulting in a CR rate of 72%. The incorporation of PDT in standard clinical practice, in combination with radiotherapy, warrants further investigation.

KW - Hematoporphyrin derivative

KW - Non-small-cell lung cancer

KW - Photodynamic therapy

KW - Photofrin

UR - http://www.scopus.com/inward/record.url?scp=34447276490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447276490&partnerID=8YFLogxK

U2 - 10.1002/lsm.20513

DO - 10.1002/lsm.20513

M3 - Article

C2 - 17565719

AN - SCOPUS:34447276490

VL - 39

SP - 394

EP - 402

JO - Lasers in Surgery and Medicine

JF - Lasers in Surgery and Medicine

SN - 0196-8092

IS - 5

ER -